Table of Contents Author Guidelines Submit a Manuscript
Critical Care Research and Practice
Volume 2016 (2016), Article ID 6794861, 7 pages
http://dx.doi.org/10.1155/2016/6794861
Research Article

Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study

1King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia
2Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia
3Department of Nursing, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia
4Adult Critical Care Medicine, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia

Received 27 March 2016; Revised 11 June 2016; Accepted 15 June 2016

Academic Editor: Samuel A. Tisherman

Copyright © 2016 Nawal Salahuddin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. von Elm, M. Egger, D. G. Altman, S. J. Pocock, P. C. Gøtzsche, and J. P. Vandenbroucke, “Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies,” British Medical Journal, vol. 335, no. 7624, pp. 806–808, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Rello, L. Vidaur, A. Sandiumenge et al., “De-escalation therapy in ventilator-associated pneumonia,” Critical Care Medicine, vol. 32, no. 11, pp. 2183–2190, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. R. Eachempati, L. J. Hydo, J. Shou, and P. S. Barie, “Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients?” The Journal of Trauma, vol. 66, no. 5, pp. 1343–1348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. J. De Waele, M. Ravyts, P. Depuydt, S. I. Blot, J. Decruyenaere, and D. Vogelaers, “De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?” Journal of Critical Care, vol. 25, no. 4, pp. 641–646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. M. L. Hibbard, T. R. Kopelman, P. J. O'Neill et al., “Empiric, broad-spectrum antibiotic therapy with an aggressive de-escalation strategy does not induce gram-negative pathogen resistance in ventilator-associated pneumonia,” Surgical Infections, vol. 11, no. 5, pp. 427–432, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Morel, J. Casoetto, R. Jospé et al., “De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit,” Critical Care, vol. 14, no. 6, article R225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Gonzalez, A. Cravoisy, D. Barraud et al., “Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients,” Critical Care, vol. 17, no. 4, article R140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Duchêne, E. Montassier, D. Boutoille, J. Caillon, G. Potel, and E. Batard, “Why is antimicrobial de-escalation under-prescribed for urinary tract infections?” Infection, vol. 41, no. 1, pp. 211–214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Garnacho-Montero, A. Gutiérrez-Pizarraya, A. Escoresca-Ortega et al., “De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock,” Intensive Care Medicine, vol. 40, no. 1, pp. 32–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Carugati, F. Franzetti, T. Wiemken et al., “De-escalation therapy among bacteraemic patients with community-acquired pneumonia,” Clinical Microbiology and Infection, vol. 21, no. 10, pp. 936.e11–936.e18, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-C. Lee, N.-Y. Lee, P.-L. Chen et al., “Impact of antimicrobial strategies on clinical outcomes of adults with septic shock and community-onset Enterobacteriaceae bacteremia: de-escalation is beneficial,” Diagnostic Microbiology and Infectious Disease, vol. 82, no. 2, pp. 158–164, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Madaras-Kelly, M. Jones, R. Remington et al., “Antimicrobial de-escalation of treatment for healthcare-associated pneumonia within the Veterans Healthcare Administration,” The Journal of Antimicrobial Chemotherapy, vol. 71, no. 2, pp. 539–546, 2016. View at Publisher · View at Google Scholar
  13. M. Falguera, A. Ruiz-González, J. A. Schoenenberger et al., “Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia,” Thorax, vol. 65, no. 2, pp. 101–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. W. Kim, J. Chung, S.-H. Choi et al., “Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial,” Critical Care, vol. 16, no. 1, article R28, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Leone, C. Bechis, K. Baumstarck et al., “De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial,” Intensive Care Medicine, vol. 40, no. 10, pp. 1399–1408, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Joung, J.-A. Lee, S.-Y. Moon et al., “Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia,” Critical Care, vol. 15, no. 2, article R79, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Shime, S. Satake, and N. Fujita, “De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients,” Infection, vol. 39, no. 4, pp. 319–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. S. Kaye, “Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia,” Journal of Hospital Medicine, vol. 7, supplement 1, pp. S13–S21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. K. V. I. Rolston, S. N. Mahajan, and R. F. Chemaly, “Antimicrobial de-escalation in cancer patients,” Infection, vol. 40, no. 2, pp. 223–224, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Apisarnthanarak, N. Bhooanusas, A. Yaprasert, and L. M. Mundy, “Carbapenem de-escalation therapy in a resource-limited setting,” Infection Control and Hospital Epidemiology, vol. 34, no. 12, pp. 1310–1313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. J. Mosier and H. Ton-That, “Making the case for de-escalation therapy in ventilator-associated pneumonia once again,” Critical Care Medicine, vol. 41, no. 7, pp. 1810–1811, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. G. Masterton, M. Casamayor, P. Musingarimi et al., “De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections,” Journal of Medical Economics, vol. 16, no. 11, pp. 1344–1356, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Bailly, O. Leroy, P. Montravers et al., “Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data,” Intensive Care Medicine, vol. 41, no. 11, pp. 1931–1940, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Mokart, G. Slehofer, J. Lambert et al., “De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study,” Intensive Care Medicine, vol. 40, no. 1, pp. 41–49, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. F. A. Khasawneh, A. Karim, T. Mahmood et al., “Antibiotic de-escalation in bacteremic urinary tract infections: potential opportunities and effect on outcome,” Infection, vol. 42, no. 5, pp. 829–834, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Garnacho-Montero, A. Escoresca-Ortega, and E. Fernández-Delgado, “Antibiotic de-escalation in the ICU: how is it best done?” Current Opinion in Infectious Diseases, vol. 28, no. 2, pp. 193–198, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Cheon, M. J. Kim, S. J. Yun, J. Y. Moon, and Y. S. Kim, “Controlling endemic multidrug-resistant Acinetobacter baumannii in intensive care units using antimicrobial stewardship and infection control,” The Korean Journal of Internal Medicine, vol. 31, no. 2, pp. 367–374, 2016. View at Publisher · View at Google Scholar
  28. L. R. Taggart, E. Leung, M. P. Muller, L. M. Matukas, and N. Daneman, “Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: a controlled interrupted time series study,” BMC Infectious Diseases, vol. 15, no. 1, article 480, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Hohn, B. Heising, S. Hertel, G. Baumgarten, M. Hochreiter, and S. Schroeder, “Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis,” Infection, vol. 43, no. 4, pp. 405–412, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Hou, Q. Wang, C. Jiang, C. Tian, H. Li, and B. Ji, “Evaluation of the short-term effects of antimicrobial stewardship in the intensive care unit at a tertiary hospital in China,” PLoS ONE, vol. 9, no. 7, article e101447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. O. Cotta, J. A. Roberts, A. Tabah, J. Lipman, D. Vogelaers, and S. Blot, “Antimicrobial stewardship of β-lactams in intensive care units,” Expert Review of Anti-Infective Therapy, vol. 12, no. 5, pp. 581–595, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. Amer, N. S. Akhras, W. A. Mahmood, and A. S. Al-Jazairi, “Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia,” Annals of Saudi Medicine, vol. 33, no. 6, pp. 547–554, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Ramsamy, D. J. J. Muckart, and K. S. S. Han, “Microbiological surveillance and antimicrobial stewardship minimise the need for ultrabroad-spectrum combination therapy for treatment of nosocomial infections in a trauma intensive care unit: an audit of an evidence-based empiric antimicrobial policy,” South African Medical Journal, vol. 103, no. 6, pp. 371–376, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Slain, A. R. Sarwari, K. O. Petros et al., “Impact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit setting,” Critical Care Research and Practice, vol. 2011, Article ID 416426, 5 pages, 2011. View at Publisher · View at Google Scholar
  35. E. de Jong, J. A. van Oers, A. Beishuizen et al., “Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial,” The Lancet Infectious Diseases, vol. 16, no. 7, pp. 819–827, 2016. View at Publisher · View at Google Scholar